Is FPHAF or RYLD a better dividend investment in 2026?

FPHAF currently yields 60.61% with a 5% 5-year dividend growth rate. RYLD yields 12.39% with 5% growth. The better choice depends on your goal: FPHAF offers higher current income.

What is the dividend yield difference between FPHAF and RYLD?

FPHAF has a forward dividend yield of 60.61% ($2.00/share annually). RYLD yields 12.39% ($1.81/share annually). The yield gap is 48.22 percentage points.

Home › Compare › FPHAF vs RYLD

FPHAF vs RYLD: Dividend Comparison 2026

FPHAF yields 60.61% · RYLD yields 12.39%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 FPHAF wins by $625.9K in total portfolio value

INVESTMENT

TIME HORIZON10 years

FPHAF

● Live price

60.61%

Share price

$3.30

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$671.2K

Annual income

$158,074.64

Full FPHAF calculator →

RYLD

● Live price

12.39%

Share price

$14.64

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$45.3K

Annual income

$2,682.98

Full RYLD calculator →

Portfolio growth — FPHAF vs RYLD

📍 FPHAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	FPHAF	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, FPHAF + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

FPHAF pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FPHAF

Annual income on $10K today (after 15% tax)

$5,151.52/yr

After 10yr DRIP, annual income (after tax)

$134,363.44/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,053.44/yr

After 10yr DRIP, annual income (after tax)

$2,280.53/yr

At 15% tax rate, FPHAF beats the other by $132,082.91/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FPHAF + RYLD for your $10,000?

FPHAF: 50%RYLD: 50%

100% RYLD50/50100% FPHAF

Portfolio after 10yr

$358.2K

Annual income

$80,378.81/yr

Blended yield

22.44%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FPHAF buys

RYLD buys

No recent congressional trades found for FPHAF or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricFPHAFRYLD

Forward yield	60.61% ✓	12.39%
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$671.2K ✓	$45.3K
Annual income after 10y	$158,074.64 ✓	$2,682.98
Total dividends collected	$557.6K ✓	$19.4K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: FPHAF vs RYLD ($10,000, DRIP)

Year	FPHAF Portfolio	FPHAF Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$16,761	$6,060.61	$11,939	$1,239.34	+$4.8K → FPHAF
2	$27,427	$9,493.40	$14,158	$1,382.89	+$13.3K → FPHAF
3	$43,866	$14,518.80	$16,682	$1,532.59	+$27.2K → FPHAF
4	$68,638	$21,701.63	$19,537	$1,687.64	+$49.1K → FPHAF
5	$105,179	$31,735.61	$22,752	$1,847.20	+$82.4K → FPHAF
6	$157,990	$45,448.98	$26,355	$2,010.43	+$131.6K → FPHAF
7	$232,853	$63,803.27	$30,376	$2,176.45	+$202.5K → FPHAF
8	$337,036	$87,884.16	$34,847	$2,344.43	+$302.2K → FPHAF
9	$479,513	$118,883.79	$39,800	$2,513.54	+$439.7K → FPHAF
10	$671,153	$158,074.64	$45,269	$2,682.98	+$625.9K → FPHAF

FPHAF vs RYLD: Complete Analysis 2026

FPHAF — Stock

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Full FPHAF Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this FPHAF vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FPHAF vs SCHD FPHAF vs JEPI FPHAF vs O FPHAF vs KO FPHAF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.